Dr. Reddy’s Launches Bosutinib Tablets in the U.S. Market

Dr. Reddy’s Laboratories has announced the launch of Bosutinib Tablets, a generic version of Bosulif®, in the United States. The product launch expands the company’s oncology portfolio and provides a generic treatment option for eligible patients with certain types of leukemia.

A New Addition to the Oncology Portfolio

Bosutinib is a tyrosine kinase inhibitor used in the treatment of specific forms of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Dr. Reddy’s has introduced the generic product following approval of its Abbreviated New Drug Application, expanding access to this important oncology medicine in the U.S. market.

Product Details

① Product: Bosutinib Tablets

② Reference Medicine: Bosulif®

③ Therapeutic Area: Oncology

④ Treatment Focus: Philadelphia chromosome-positive chronic myeloid leukemia

⑤ Market: United States

⑥ Company: Dr. Reddy’s Laboratories

Available Strengths

The newly launched Bosutinib Tablets are available in multiple strengths to support prescribed treatment requirements:

◆ 100 mg

◆ 400 mg

◆ 500 mg

The availability of different strengths provides flexibility for treatment regimens prescribed by healthcare professionals.

Expanding Access to Cancer Treatment

Bosutinib is used for adult patients with chronic-phase, accelerated-phase or blast-phase Ph+ CML in specific treatment settings. By launching a generic version, Dr. Reddy’s is expanding its portfolio of oncology medicines while offering an additional treatment option in the U.S. pharmaceutical market.

Potential Treatment Areas

▸ Chronic-Phase Ph+ CML — For eligible adult patients.

▸ Accelerated-Phase Ph+ CML — Used in specific clinical treatment settings.

▸ Blast-Phase Ph+ CML — Supporting treatment for advanced stages of the disease.

▸ Oncology Care — Adding another generic medicine to Dr. Reddy’s cancer-treatment portfolio.

A Strategic Step in the U.S. Generics Market

The launch of Bosutinib Tablets reflects Dr. Reddy’s continued focus on expanding its portfolio in complex and specialty generic medicines. Oncology remains an important therapeutic area where generic alternatives can contribute to broader treatment availability and provide additional options for healthcare providers and patients.

Market Significance

The introduction of Bosutinib Tablets in 100 mg, 400 mg and 500 mg strengths strengthens Dr. Reddy’s presence in the U.S. oncology market. The launch adds another specialized generic product to the company’s portfolio and supports its broader strategy of delivering pharmaceutical products across key therapeutic areas.